Takeda Pharmaceutical Company Limited Share Price Sao Paulo
Stocks
TAKP34
BRTAKPBDR006
Pharmaceuticals
OTC Markets Traded|
Delayed
Sao Paulo
08:21:49 27/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 109.00 BRL | +4.31% |
|
+9.55% | +31.07% |
| 26/10 | Takeda Pharmaceutical Eyes 2027 Japan Filing for Gastric Cancer Treatment | MT |
| 26/10 | Takeda to seek Japan approval for gastric cancer drug next year | RE |
| Market Cap | 10,07100Cr 34TCr 6.38TCr 5.72TCr 5.29TCr 4.79TCr 8.96TCr 6,05900Cr 9.07TCr 63TCr 25TCr 3,17600Cr 24TCr 23TCr | P/E 2027 * |
50x | P/E 2028 * | 31.7x |
|---|---|---|---|---|---|
| Enterprise Value | 13,97800Cr 47TCr 8.85TCr 7.95TCr 7.34TCr 6.65TCr 12TCr 8,41000Cr 13TCr 88TCr 35TCr 4,40800Cr 33TCr 33TCr | EV / Sales 2027 * |
2.97x | EV / Sales 2028 * | 2.87x |
| Free-Float |
99.18% | Yield 2027 * |
3.24% | Yield 2028 * | 3.3% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +4.31% | ||
| 1 week | +9.55% | ||
| Current month | +10.02% | ||
| 1 month | +10.02% | ||
| 3 months | +32.41% | ||
| 6 months | +21.84% | ||
| Current year | +31.07% |
| 1 week | 104.5 |  | 109 |
| 1 month | 90 | | 109 |
| Current year | 76.32 | | 109 |
| 1 year | 70.8 | | 109 |
| 3 years | 66.46 | | 109 |
| 5 years | 66.1 | | 109 |
| 10 years | 66.1 | | 109 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 61 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.31% | +9.55% | - | - | 6.48TCr | |
| +0.53% | +1.40% | +57.12% | +127.78% | 1,14300Cr | |
| +0.91% | +5.08% | +44.91% | +84.23% | 65TCr | |
| +0.26% | +0.83% | +26.20% | +102.38% | 51TCr | |
| -0.05% | +1.73% | +52.74% | +65.27% | 38TCr | |
| -0.69% | -6.12% | +61.68% | +37.04% | 35TCr | |
| +0.34% | +1.84% | +30.70% | +52.69% | 29TCr | |
| -0.45% | +1.19% | +2.89% | +24.92% | 26TCr | |
| +0.51% | +2.75% | +54.20% | +71.13% | 24TCr | |
| +0.33% | +3.94% | +35.40% | +105.24% | 20TCr | |
| Average | +0.58% | +0.85% | +40.65% | +74.52% | 44.75TCr | |
| Weighted average by Cap. | +0.33% | +0.71% | +44.52% | +87.00% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,70200Cr 16TCr 2.98TCr 2.67TCr 2.47TCr 2.24TCr 4.18TCr 2,82900Cr 4.23TCr 30TCr 12TCr 1,48300Cr 11TCr 11TCr | 4,79600Cr 16TCr 3.04TCr 2.73TCr 2.52TCr 2.28TCr 4.27TCr 2,88500Cr 4.32TCr 30TCr 12TCr 1,51200Cr 11TCr 11TCr |
| Net income | 20TCr 664.91Cr 124.35Cr 111.61Cr 103.05Cr 93Cr 174.66Cr 12TCr 176.8Cr 1.24TCr 490.68Cr 6.19TCr 466.78Cr 456.8Cr | 32TCr 1.09TCr 204.6Cr 183.63Cr 169.55Cr 153.76Cr 287.37Cr 19TCr 290.9Cr 2.03TCr 807.33Cr 10TCr 768.01Cr 751.58Cr |
| Net Debt | 3,90700Cr 13TCr 2.47TCr 2.22TCr 2.05TCr 1.86TCr 3.48TCr 2,35100Cr 3.52TCr 25TCr 9.77TCr 1,23200Cr 9.29TCr 9.09TCr | 3,70500Cr 13TCr 2.35TCr 2.11TCr 1.94TCr 1.76TCr 3.3TCr 2,22900Cr 3.34TCr 23TCr 9.26TCr 1,16800Cr 8.81TCr 8.62TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 27/26/27 | R$109.00 | +4.31% | 14 |
| 26/26/26 | R$104.50 | +5.03% | 4 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- TAKP34 Stock
Select your edition
All financial news and data tailored to specific country editions
